(S)-1-((S)-1-(3-((1R,2R)-1-amino-2-hydroxypropyl)-1,2,4-oxadiazol-5-yl)-2-(4-hydroxyphenyl)ethylcarbamoyl)pyrrolidine-2-carboxylic acid

ID: ALA4476446

Chembl Id: CHEMBL4476446

PubChem CID: 155538135

Max Phase: Preclinical

Molecular Formula: C19H25N5O6

Molecular Weight: 419.44

Molecule Type: Unknown

Associated Items:

Names and Identifiers

Canonical SMILES:  C[C@@H](O)[C@H](N)c1noc([C@H](Cc2ccc(O)cc2)NC(=O)N2CCC[C@H]2C(=O)O)n1

Standard InChI:  InChI=1S/C19H25N5O6/c1-10(25)15(20)16-22-17(30-23-16)13(9-11-4-6-12(26)7-5-11)21-19(29)24-8-2-3-14(24)18(27)28/h4-7,10,13-15,25-26H,2-3,8-9,20H2,1H3,(H,21,29)(H,27,28)/t10-,13+,14+,15+/m1/s1

Standard InChI Key:  XIYKWOOOEYTRIY-KJEVXHAQSA-N

Alternative Forms

  1. Parent:

    ALA4476446

    ---

Associated Targets(non-human)

Cd274 Programmed cell death 1 ligand 1 (33 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
Splenocyte (1641 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: UnknownTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Calculated Properties

Molecular Weight: 419.44Molecular Weight (Monoisotopic): 419.1805AlogP: 0.70#Rotatable Bonds: 7
Polar Surface Area: 175.04Molecular Species: ACIDHBA: 8HBD: 5
#RO5 Violations: HBA (Lipinski): 11HBD (Lipinski): 6#RO5 Violations (Lipinski): 2
CX Acidic pKa: 3.66CX Basic pKa: 7.05CX LogP: -1.85CX LogD: -2.28
Aromatic Rings: 2Heavy Atoms: 30QED Weighted: 0.43Np Likeness Score: -0.65

References

1. Wang T, Wu X, Guo C, Zhang K, Xu J, Li Z, Jiang S..  (2019)  Development of Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Signaling Pathway.,  62  (4): [PMID:30247903] [10.1021/acs.jmedchem.8b00990]
2. Pan C, Yang H, Lu Y, Hu S, Wu Y, He Q, Dong X..  (2021)  Recent advance of peptide-based molecules and nonpeptidic small-molecules modulating PD-1/PD-L1 protein-protein interaction or targeting PD-L1 protein degradation.,  213  [PMID:33454550] [10.1016/j.ejmech.2021.113170]
3. Lin X, Lu X, Luo G, Xiang H..  (2020)  Progress in PD-1/PD-L1 pathway inhibitors: From biomacromolecules to small molecules.,  186  [PMID:31761384] [10.1016/j.ejmech.2019.111876]

Source